- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Biocon Limited — Updates, 02-12-2025: Press Release
02-12-2025 | 09:04 am
02-12-2025 | 09:04 am
Biocon Biologics secured market entry for its Denosumab biosimilars, Vevzuo® and Evfraxy®, in Europe and key international markets via a settlement agreement. This move significantly broadens its global presence in oncology and bone health therapeutic areas.
No comments yet. Be the first to comment!